OR
ORIC.US Oric Pharmaceuticals Inc
- Market cap
- USD 815M
- P/E
- -
- P/B
- 2.13x
- ROE
- -49.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ORIC.US undervalued?
Graham numberThe Graham number of Oric Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oric Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Oric Pharmaceuticals Inc yet.
Oric Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth fact…
Full company profileOric Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Oric Pharmaceuticals Inc annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -900K | -900K | -1.00M | -970K | -897K | -966K | -1.03M | -1.11M | -1.22M | - |
| Operating Income | -22.5M | -22.4M | -28.6M | -74.2M | -78.9M | -91.8M | -111M | -143M | -143M | -182M |
| EBITDA | -21.1M | -21.5M | -25.9M | -48.4M | -78.0M | -85.8M | -99.7M | -127M | -128M | -176M |
| Net Income | -22.0M | -21.4M | -26.9M | -73.7M | -77.7M | -89.1M | -101M | -128M | -129M | -167M |
| EPS | -16 | -12 | -0.90 | -3.36 | -2.05 | -2.25 | -1.96 | -1.83 | -1.47 | -1.54 |
| Balance Sheet | ||||||||||
| Total Assets | 30.0M | 46.7M | 94.1M | 299M | 299M | 250M | 255M | 274M | 409M | 367M |
| Total Liabilities | 4.30M | 111M | 6.12M | 9.22M | 25.7M | 28.0M | 30.6M | 31.0M | 24.5M | 27.4M |
| Shareholders' Equity | 25.7M | -64.4M | 88.0M | 290M | 273M | 222M | 224M | 243M | 384M | 340M |
| Cash & Short-term Investments | 25.8M | 42.6M | 89.2M | 294M | 237M | 206M | 208M | 256M | 281M | 261M |
| Total Debt | - | - | - | - | 1.93M | 12.1M | 10.2M | 3.18M | 3.33M | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -20.8M | -20.7M | -23.5M | -45.3M | -59.5M | -75.1M | -85.7M | -113M | -111M | -141M |
| Capital Expenditure | 486K | 525K | 768K | 667K | 939K | 2.08M | 849K | 1.19M | 712K | 955K |
| Free Cash Flow | -21.3M | -21.2M | -24.3M | -45.9M | -60.5M | -77.2M | -86.5M | -114M | -112M | -141M |
| Ratios | ||||||||||
| ROE | -85.6% | - | -30.6% | -25.4% | -28.5% | -40.1% | -44.9% | -52.6% | -33.7% | -49.2% |
| ROA | -73.4% | -45.7% | -28.6% | -24.7% | -26.0% | -35.6% | -39.5% | -46.6% | -31.7% | -45.5% |
| Debt to Equity | - | - | - | - | 0.01x | 0.05x | 0.05x | 0.01x | 0.01x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Oric Pharmaceuticals Inc dividends
Oric Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns Oric Pharmaceuticals Inc
- Insiders 1.69%
- Institutions 98.31%
- Public & others 0.00%
- Shares outstanding 104M
- Free float 88.7M
Top funds holding ORIC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.96M | 2.86% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.59M | 2.50% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 1.88M | 1.82% | 0.00% | Oct 2026 |
| ACAP Strategic A | 1.85M | 1.79% | -16.87% | Jun 2026 |
| Franklin Biotechnology Discv A(acc)USD | 1.22M | 1.18% | 0.00% | Sep 2026 |
| T. Rowe Price Health Sciences | 1.20M | 1.15% | 0.00% | Sep 2026 |
| Eventide Healthcare & Life Sciences I | 951K | 0.92% | 0.00% | Jun 2026 |
| T. Rowe Price New Horizons | 903K | 0.87% | -11.03% | Sep 2026 |
| Fidelity Small Cap Index | 819K | 0.79% | +0.09% | Aug 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 788K | 0.76% | -37.56% | Sep 2026 |
| Fidelity Growth Company Fund | 717K | 0.69% | 0.00% | Aug 2026 |
| Franklin Biotechnology Discovery A | 659K | 0.64% | 0.00% | Sep 2026 |
| Belfius Equities Cure C Cap | 547K | 0.53% | +30.02% | Apr 2026 |
| iShares Biotechnology ETF | 532K | 0.51% | -0.19% | Oct 2026 |
| Biotech Growth Ord | 491K | 0.47% | -27.11% | Jul 2026 |
| iShares Russell 2000 Value ETF | 483K | 0.47% | 0.00% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 480K | 0.46% | +0.23% | Oct 2026 |
| Advantage Advisers Xanthus | 443K | 0.43% | -15.77% | Sep 2026 |
| Vanguard Russell 2000 ETF | 435K | 0.42% | +1.20% | Sep 2026 |
| Fidelity Extended Market Index | 421K | 0.41% | +4.17% | Sep 2026 |
Top institutions holding ORIC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Nextech Invest, Ltd. | 7.16M | 6.91% | 0.00% | Jun 2026 |
| BlackRock Inc | 6.82M | 6.58% | +14.03% | Jun 2026 |
| EcoR1 Capital, LLC | 6.73M | 6.49% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 6.62M | 6.38% | +22.83% | Jun 2026 |
| Viking Global Investors LP | 5.13M | 4.95% | -11.98% | Jun 2026 |
| State Street Corp | 4.89M | 4.72% | +32.19% | Jun 2026 |
| SR ONE CAPITAL MANAGEMENT, LP | 4.62M | 4.45% | +2.23% | Jun 2026 |
| VR Adviser, LLC | 4.32M | 4.17% | 0.00% | Jun 2026 |
| NEA Management Company, LLC | 4.12M | 3.97% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.95M | 3.81% | +7.16% | Jun 2026 |
| AIHC Capital Management Limited | 3.83M | 3.69% | +55.66% | Jun 2026 |
| Alkeon Capital Management, LLC | 3.74M | 3.61% | -16.98% | Jun 2026 |
| Column Group LLC | 3.54M | 3.42% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 3.00M | 2.89% | 0.00% | Jun 2026 |
| FMR Inc | 2.64M | 2.54% | +8.27% | Jun 2026 |
| Citadel Advisors Llc | 2.60M | 2.50% | +7.12% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.45M | 2.37% | +66.14% | Jun 2026 |
| Geode Capital Management, LLC | 2.09M | 2.02% | +13.67% | Jun 2026 |
| First Turn Management LLC | 2.02M | 1.95% | 0.00% | Jun 2026 |
| Orbimed Advisors LLC | 2.02M | 1.94% | -25.20% | Jun 2026 |
Oric Pharmaceuticals Inc company profile
- Company name
- Oric Pharmaceuticals Inc
- Ticker
- ORIC.US
- Exchange
- USA Stocks
- Listed since
- Apr 24, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 111
- Fiscal year end
- December
- Address
- 240 E. Grand Ave, South San Francisco, CA, United States, 94080
- Phone
- 650 388 5600
- Website
- oricpharma.com
About Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Oric Pharmaceuticals Inc management
10- Dr. Richard A. Heyman Ph.D.Founder, Independent Chairman & Member of Scientific Advisory Board · born 1957
- Dr. Jacob M. Chacko M.B.A., M.D.President, CEO & Director · born 1979
- Mr. Dominic G. Piscitelli CPA, M.B.A.Chief Financial Officer · born 1975
- Dr. Pratik S. Multani M.D., M.S.Chief Medical Officer · born 1967
- Dr. Charles L. Sawyers B.A., M.D., Ph.D.Founder & Member of Scientific Advisory Board · born 1959
- Dr. Scott W. Lowe Ph.D.Founder & Member of Scientific Advisory Board
- Dr. Kevin Brodbeck Ph.D.Chief Technical Officer
- Dr. Lori Sickels Friedman Ph.D.Chief Scientific Officer · born 1965
- Dr. Christian V. Kuhlen Esq., J.D., M.D.General Counsel & Chief Compliance Officer · born 1973
- Mr. Daniel IazzettiVP & Head of People